UPDATE : Saturday, November 16, 2019
상단여백
'Eisai's Lenvima extends survival period, improves patients’ quality of life' by Lee Han-soo 2019-10-16 18:22
Foreign patients receiving plastic surgery hit record high in 2018 by Kwak Sung-sun 2019-10-16 15:28
‘New drug approval process takes about 300 days in Korea’ by Lee Han-soo 2019-10-16 15:06
State organs squandered ₩8.2 billion; failed to spot Invossa problem by Kwak Sung-sun 2019-10-16 15:06
[Exclusive] Samsung admits it failed to develop Rituxan biosimilar by Jeong Sae-im 2019-10-16 14:16
라인
Eulji Medical Center transfers advanced medical expertise to Bangladesh by Lee Han-soo 2019-10-16 11:28
Seoul Medical Center transfer public healthcare know-how to developing countries by Lee Han-soo 2019-10-15 18:02
‘Genome analysis-based therapy to help realize precision medicine’ by Lee Han-soo 2019-10-15 17:50
'High ozone levels can aggravate dry eye symptoms' by Lee Han-soo 2019-10-15 17:50
Merck Korea forcefully shuts down general medicine biz by Kim Yun-mi 2019-10-15 15:51
라인
Galderma Korea’s key strategy: choice and concentration by Kim Yun-mi 2019-10-15 13:56
Korea brings up Fukushima’s radioactive water disposal issue at WHO by Lee Han-soo 2019-10-15 12:54
Medytox, Daewoong still in dispute over Nabota's spore appraisal by Lee Han-soo 2019-10-15 11:28
Kolon Life Science shares surge after TissueGene’s survival by Jeong Sae-im 2019-10-14 18:01
Lilly’s Taltz shows superiority to Tremfya in treating psoriasis patients by Lee Han-soo 2019-10-14 18:01
라인
First lung disease reported here with suspected ties to vaping by Lee Han-soo 2019-10-14 18:01
HLB merges with Elevar to own rivoceranib rights by Jeong Sae-im 2019-10-14 14:43
HanAll's Chinese partner ends P2 trial of dry eye treatment by Lee Han-soo 2019-10-14 14:08
[Special] How are Korean employees coping with big-pharma M&As? by Kim Yun-mi 2019-10-14 13:45
Sanofi releases data showing improved survival for prostate cancer treatment by Lee Han-soo 2019-10-14 12:16
여백
여백
여백
Back to Top